Skip to main content
Springer logoLink to Springer
. 2022 Mar 7;42(3):277. doi: 10.1007/s40261-022-01123-z

Correction to: Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)

Stewart J Tepper 1, Jessica Ailani 2, Janet H Ford 3,✉, Russell M Nichols 4, Lily Q Li 4, Phebe Kemmer 5, Austin L Hand 6, Antje Tockhorn-Heidenreich 7
PMCID: PMC8930929  PMID: 35254628

Correction to: Clinical Drug Investigation10.1007/s40261-021-01115-5

The original version of this article unfortunately contained a mistake. Affiliation details for Stewart J. Tepper and Janet H. Ford were incorrect and Zip Code for affiliations 4 and 5 should be 46285.

The correct affiliations should be

Stewart J. Tepper

Department of Neurology, Geisel School of Medicine at Dartmouth, 1 Rope Ferry Rd, Hanover, NH 03755, USA.

Janet H. Ford

Health Outcomes and Real-World Evidence, Biomedicines, Eli Lilly and Company, Lilly Corporate Center, 893 Delaware St, Indianapolis, IN 46285, USA.

The original article has been corrected.


Articles from Clinical Drug Investigation are provided here courtesy of Springer

RESOURCES